Alnylam Pharmaceuticals is already making progress on its July 2023 deal with Roche to co-develop and commercialize zilebesiran, the former’s investigational RNAi therapeutic. The Cambridge biotech reported positive topline Phase II results Thursday for its partnered gene-silencing therapy to treat hypertension.
Tag Archive for: hypertension
At the recommendation of an independent data monitoring committee, J&J’s Janssen decided to stop the MACiTEPH trial in chronic thromboembolic pulmonary hypertension due to futility.
The trial data reinforces the potential for zilebesiran to offer “new possibilities in a field of medicine that has seen limited innovation in nearly 20 years,” said Simon Fox, program lead for the drug’s development.
Under the deal, Roche will make an upfront payment of $310 million in cash. Alnylam is also entitled to development, regulatory and sales milestones, with a potential contract value of up to $2.8 billion.
Plaintiffs accused Novartis and Par Pharmaceutical of entering an illegal “reverse payment” agreement to delay launches of less expensive, generic versions of Exforge, which treats hypertension to lower blood pressure and reduce the risk of strokes.
The pharma titan adds an intriguing blood pressure medication to its line up with a buyout of CinCor.
Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its Exforge hypertension drug.
An experimental COVID-19 vaccine in the form of an oral tablet has shown promising immune responses in a small preliminary trial designed mainly to evaluate its safety; High blood pressure more than doubles the risk of hospitalization during COVID-19 infections with the coronavirus Omicron variant, even in people who are fully vaccinated and boosted, a U.S. study showed.
